EPA Levels May Be Tied To HF Rates In High-Risk Patients Taking Icosapent Ethyl, Study Indicates

Healio (6/1, Vecchione) reports, “In patients from the REDUCE-IT trial assigned icosapent ethyl, those who achieved high or moderate levels of eicosapentaenoic acid had better HF outcomes compared with those who achieved low levels,” researchers concluded...